MedTrace Logo

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

NCT04906213 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-27

No results posted yet for this study

Summary

CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.

Conditions

  • Kidney Transplant; Complications
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Empagliflozin10Mg Tab

Empagliflozin10 Mg daily or placebo daily for 18 months

DRUG

Placebo

10Mg Placebo Tab

Sponsors & Collaborators

Principal Investigators

  • Myles Wolf, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2026-01-22
Completion
2026-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906213 on ClinicalTrials.gov